Milestone Scientific Inc
Milestone Scientific Inc develops and markets computer-controlled drug delivery systems for use in dental and medical applications, generating revenue primarily through the sale of its proprietary devices and related consumables.
Business. Milestone Scientific Inc (MLSS.K) is a healthcare services and equipment company specializing in advanced medical equipment and technology. The firm operates within the Advanced Medical Equipment & Technology industry, focusing on product sales. Headquarters and specific operating segment details are not provided in the available data. The company is listed on the NYSE under the ticker symbol MLSS.K.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Milestone Scientific Inc (MLSS.K) is a healthcare services and equipment company specializing in advanced medical equipment and technology. The firm operates within the Advanced Medical Equipment & Technology industry, focusing on product sales. Headquarters and specific operating segment details are not provided in the available data. The company is listed on the NYSE under the ticker symbol MLSS.K.
Milestone Scientific Inc operates with a market capitalization of $27.41 million and a price-to-book ratio of 9.75, indicating a premium valuation relative to its book value. The company's liquidity position is characterized by $1.11 million in cash and equivalents, but it is offset by negative operating and free cash flows of -$2.92 million and -$5.66 million, respectively, signaling potential short-term liquidity constraints. The current ratio of 1.81 suggests the company can cover its current liabilities with its current assets, but the negative operating cash flow raises concerns about its ability to sustain operations without external financing.
Profitability metrics reveal a challenging financial landscape for Milestone Scientific Inc. The company reported a net loss of $5.72 million and an operating loss of $5.70 million, resulting in a return on equity of -2.03% and a return on assets of -0.73%, both significantly below industry norms. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit.
Geographically, Milestone Scientific Inc's revenue is not disclosed by region, but its business model is heavily reliant on the sale of proprietary devices and consumables, which may expose it to market concentration risks in the dental and medical sectors. The company's exposure to these segments is not diversified, and any downturn in demand for its products could have a material impact on its financial performance.
Looking ahead, the company's growth trajectory is uncertain. Analysts have provided a mean price target of $1.00, which is significantly higher than the current market price of $0.31, but the lack of strong buy recommendations and the presence of only two buy ratings suggest limited confidence in the company's near-term prospects. The company's revenue history does not provide a clear indication of growth, and the absence of positive operating cash flow further complicates its ability to invest in future growth initiatives.
Risk factors for Milestone Scientific Inc include its negative net income and operating income, which could lead to increased financial leverage or the need for additional financing. The company's debt-to-equity ratio of 0.3 is relatively low, but the negative cash flows and operating losses could increase this ratio if the company needs to take on more debt to fund operations. The risk assessment indicates low liquidity and dilution risks, but the negative cash flows and operating losses could change this if the company needs to issue more shares to raise capital.
Recent events and filings do not indicate any immediate liquidity or dilution flags, but the company's financial performance suggests that it may need to seek additional financing in the near term. The absence of positive cash flows and the presence of negative operating and free cash flows highlight the need for the company to address its financial challenges to maintain its operations and growth prospects.
- Milestone Scientific Inc is trading at a price-to-book ratio of 9.75, indicating a premium valuation despite negative earnings.
- The company reported a net loss of $5.72 million and an operating loss of $5.70 million, with a return on equity of -2.03% and a return on assets of -0.73%.
- Milestone Scientific Inc has $1.11 million in cash and equivalents but is generating negative operating and free cash flows, raising concerns about its liquidity.
- Analysts have provided a mean price target of $1.00, but the lack of strong buy recommendations suggests limited confidence in the company's near-term prospects.
- The company's debt-to-equity ratio is 0.3, but the negative cash flows and operating losses could increase this ratio if the company needs to take on more debt to fund operations.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,04 |
| Revenue | —no estimate | —no estimate | 9,9M USD |
| Operating income | —no estimate | —no estimate | -3,7M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Milestone Scientific Inc Market data — financials · 2026-05-28
- Milestone Scientific Inc Market data — analyst estimates · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
- 10% owner · Common Stock, Par Value $0.001Sold 100 000 @ $0,44$44K · 2025-10-24
- 10% owner · Common Stock, Par Value $0.001Sold 80 000 @ $0,43$34K · 2025-10-23
- 10% owner · Common Stock, Par Value $0.001Sold 14 427 @ $0,45$6K · 2025-10-22
- 10% owner · Common Stock, Par Value $0.001Sold 40 000 @ $0,44$18K · 2025-10-21
- 10% owner · Common Stock, Par Value $0.001Sold 24 034 @ $0,45$11K · 2025-10-20
- 10% owner · Common Stock, Par Value $0.001Sold 30 000 @ $0,54$16K · 2025-10-14
- 10% owner · Common Stock, Par Value $0.001Sold 10 000 @ $0,55$6K · 2025-10-13
- 10% owner · Common Stock, Par Value $0.001Sold 10 158 @ $0,55$6K · 2025-10-10
- 10% owner · Common Stock, Par Value $0.001Sold 30 000 @ $0,47$14K · 2025-10-08
- 10% owner · Common Stock, Par Value $0.001Sold 10 000 @ $0,45$4K · 2025-10-07
- 10% owner · Common Stock, Par Value $0.001Sold 10 000 @ $0,45$4K · 2025-10-03
- 10% owner · Common Stock, Par Value $0.001Sold 9 210 @ $0,45$4K · 2025-10-03
- 10% owner · Common Stock, Par Value $0.001Sold 10 000 @ $0,59$6K · 2025-09-11
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Total assets (YoY) (2025-12-31 vs 2024-12-31): -20.3%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -16.7%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 26.0%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -51.8%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -47.7%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 15.7%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 0.1%Derived (calculated)
- Return on equity (FY 2025-12-31): -203.4%Derived (calculated)
- Return on assets (FY 2025-12-31): -73.3%Derived (calculated)
- Current ratio (FY 2025-12-31): 1.81xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 1.78xDerived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -16.7%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 16.9%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -21.4%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 49.4%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): -0.4%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -66.2%Derived (calculated)
- Total liabilities (annual): USD 4.99MSEC XBRL filing
- Total assets (annual): USD 7.81MSEC XBRL filing
- Current liabilities (annual): USD 4.13MSEC XBRL filing
- Current assets (annual): USD 7.48MSEC XBRL filing
- Gross profit (annual): USD 6.41MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing
- Operating income (annual): USD -5.7MSEC XBRL filing